Analysts expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to post sales of $940,000.00 for the current quarter, according to Zacks. Eight analysts have made estimates for Paratek Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $400,000.00 and the highest estimate coming in at $2.19 million. Paratek Pharmaceuticals reported sales of $10,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 9,300%. The company is scheduled to announce its next earnings results on Wednesday, May 8th.
On average, analysts expect that Paratek Pharmaceuticals will report full-year sales of $18.44 million for the current year, with estimates ranging from $10.03 million to $57.71 million. For the next year, analysts forecast that the company will report sales of $54.01 million, with estimates ranging from $22.58 million to $131.17 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). Paratek Pharmaceuticals had a negative return on equity of 149.09% and a negative net margin of 656.41%. The firm had revenue of $17.02 million for the quarter, compared to analysts’ expectations of $16.50 million.
A number of research firms recently issued reports on PRTK. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 14th. HC Wainwright restated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Thursday, February 28th. LADENBURG THALM/SH SH set a $18.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. Canaccord Genuity boosted their target price on shares of Paratek Pharmaceuticals from $14.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, January 16th. Finally, Wedbush restated an “outperform” rating on shares of Paratek Pharmaceuticals in a report on Wednesday, March 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $23.25.
A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in Paratek Pharmaceuticals by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 337,110 shares of the specialty pharmaceutical company’s stock worth $3,271,000 after buying an additional 20,476 shares during the period. Bank of New York Mellon Corp grew its stake in Paratek Pharmaceuticals by 5.7% during the third quarter. Bank of New York Mellon Corp now owns 136,376 shares of the specialty pharmaceutical company’s stock worth $1,323,000 after buying an additional 7,332 shares during the period. BlackRock Inc. grew its stake in Paratek Pharmaceuticals by 3.6% during the third quarter. BlackRock Inc. now owns 2,677,154 shares of the specialty pharmaceutical company’s stock worth $25,967,000 after buying an additional 93,764 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Paratek Pharmaceuticals during the third quarter worth approximately $1,860,000. Finally, MetLife Investment Advisors LLC grew its stake in Paratek Pharmaceuticals by 75.5% during the third quarter. MetLife Investment Advisors LLC now owns 28,473 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 12,251 shares during the period. Hedge funds and other institutional investors own 74.30% of the company’s stock.
Paratek Pharmaceuticals stock traded down $0.40 during trading on Friday, reaching $5.92. The company had a trading volume of 535,111 shares, compared to its average volume of 301,682. Paratek Pharmaceuticals has a 12-month low of $4.50 and a 12-month high of $14.15. The company has a market cap of $202.63 million, a price-to-earnings ratio of -1.66 and a beta of 1.52. The company has a debt-to-equity ratio of 4.81, a quick ratio of 14.41 and a current ratio of 14.41.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Read More: Marijuana Stocks Future Looks Bright
Get a free copy of the Zacks research report on Paratek Pharmaceuticals (PRTK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.